- TRADE NAME: Xermelo (Lexicon)
- INDICATIONS: Carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy for adults inadequately controlled by SSA therapy
- CLASS: Tryptophan hydroxylase inhibitor
- HALF-LIFE: <1 hour
- FDA APPROVAL DATE: 02/28/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A4 substrates - PREGNANCY: No available data to inform drug-associated risk
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
